Goldman Sachs’s Cymabay Therapeutics CBAY Stock Holding History

Goldman Sachs’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-75,000	Closed	-$254K	–	6998
2021 Q4	$254K	Hold	75,000	–	–	﹤0.01%	5760
2021 Q3	$274K	Buy	+75,000	New	+$295K	﹤0.01%	5556

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Goldman Sachs's CBAY Position: Q1 2024 in Review

Goldman Sachs sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 630,735 shares — an estimated $14.9M sold.

Goldman Sachs first reported a position in CBAY in Q4 2014 and held it in 27 quarters. The position peaked at $14.9M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Goldman Sachs reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Goldman Sachs sold 630,735 Cymabay Therapeutics shares in Q1 2024, an estimated $14.9M.
Goldman Sachs first reported a position in Cymabay Therapeutics in Q4 2014 and held it in 27 quarters.
Goldman Sachs's Cymabay Therapeutics position peaked at $14.9M in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.